National Cancer Institute
U.S. National Institutes of Health |

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
About NCI
Drug Information
    Posted: 07/22/2008    Updated: 02/20/2009
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Related pages
Drug Information Summaries

Approval Process for New Cancer Treatments

Access to Investigational Drugs: Q & A
Fludarabine Phosphate

This page contains brief information about fludarabine phosphate and a collection of links to more information about the use of this drug, related research results, and ongoing clinical trials.

US Brand Name(s):Fludara
FDA Approved:Yes

Fludarabine phosphate is approved by the Food and Drug Administration (FDA) to treat refractory B-cell chronic lymphocytic leukemia (CLL). It is used in adult patients who have been treated with other chemotherapy and have not gotten better or have gotten worse.

Fludarabine phosphate is also being studied in the treatment of other types of cancer.

Information from the NCI

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trial Results: Higher Chronic Lymphocytic Leukemia Remissions with Fludarabine (11/08/2001) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Fludarabine Prolongs Leukemia Remission (12/14/2000) - Important clinical trial results for this drug, background information, and how the trial was done.

Information from the National Library of Medicine (NLM)

MedlinePlus Information on Fludarabine Phosphate - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials

Clinical Trials for Fludarabine Phosphate - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health